These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 17418595)
21. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Atmaca H; Gorumlu G; Karaca B; Degirmenci M; Tunali D; Cirak Y; Purcu DU; Uzunoglu S; Karabulut B; Sanli UA; Uslu R Eur Cytokine Netw; 2009 Sep; 20(3):121-30. PubMed ID: 19825521 [TBL] [Abstract][Full Text] [Related]
22. Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway. Li XY; Lin YC; Huang WL; Lin W; Wang HB; Lin WZ; Lin SL Med Oncol; 2012 Dec; 29(5):3374-80. PubMed ID: 22729369 [TBL] [Abstract][Full Text] [Related]
23. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines. Karabulut B; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Uslu R Mol Biol Rep; 2011 Jan; 38(1):249-59. PubMed ID: 20349282 [TBL] [Abstract][Full Text] [Related]
24. Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells. Jiang P; Zhang P; Mukthavaram R; Nomura N; Pingle SC; Teng D; Chien S; Guo F; Kesari S Oncotarget; 2016 Sep; 7(36):57932-57942. PubMed ID: 27462771 [TBL] [Abstract][Full Text] [Related]
25. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Kars MD; Işeri OD; Ural AU; Gündüz U Anticancer Res; 2007; 27(6B):4031-7. PubMed ID: 18225567 [TBL] [Abstract][Full Text] [Related]
26. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A Int J Hematol; 2003 Dec; 78(5):443-9. PubMed ID: 14704038 [TBL] [Abstract][Full Text] [Related]
27. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924 [TBL] [Abstract][Full Text] [Related]
28. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526 [TBL] [Abstract][Full Text] [Related]
29. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction. Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948 [TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Rachner TD; Singh SK; Schoppet M; Benad P; Bornhäuser M; Ellenrieder V; Ebert R; Jakob F; Hofbauer LC Cancer Lett; 2010 Jan; 287(1):109-16. PubMed ID: 19577359 [TBL] [Abstract][Full Text] [Related]
31. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Smith JA; Brown J; Martin MC; Ramondetta LM; Wolf JK Gynecol Oncol; 2004 Jan; 92(1):314-9. PubMed ID: 14751176 [TBL] [Abstract][Full Text] [Related]
32. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Ural AU; Avcu F; Candir M; Guden M; Ozcan MA Breast Cancer Res; 2006; 8(4):R52. PubMed ID: 16925824 [TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Sonnemann J; Bumbul B; Beck JF Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282 [TBL] [Abstract][Full Text] [Related]
34. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. Märten A; Lilienfeld-Toal Mv; Büchler MW; Schmidt J J Immunother; 2007; 30(4):370-7. PubMed ID: 17457212 [TBL] [Abstract][Full Text] [Related]
35. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798 [TBL] [Abstract][Full Text] [Related]
36. Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy. Wu CC; Huang YF; Hsieh CP; Chueh PJ; Chen YL Molecules; 2016 Nov; 21(12):. PubMed ID: 27916903 [TBL] [Abstract][Full Text] [Related]
37. Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines. Dirican A; Erten C; Atmaca H; Bozkurt E; Kucukzeybek Y; Varol U; Oktay Tarhan M; Karaca B; Uslu R J BUON; 2014; 19(4):1055-61. PubMed ID: 25536616 [TBL] [Abstract][Full Text] [Related]
38. Anticancer properties of zoledronic acid. Green J; Lipton A Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838 [TBL] [Abstract][Full Text] [Related]
39. [Effect of zoledronic acid on cell proliferation and apoptosis of human periodontal fibroblasts]. Fu Q; Cui C; Xuan B; Guo Y; Liu C; Zhang J Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Nov; 50(11):667-70. PubMed ID: 26757761 [TBL] [Abstract][Full Text] [Related]
40. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? Michailidou M; Brown HK; Lefley DV; Evans A; Cross SS; Coleman RE; Brown NJ; Holen I J Vasc Res; 2010; 47(6):481-93. PubMed ID: 20431297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]